Summary Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Gamma-aminobutyric acid receptor subunit gamma-2 is a protein encoded by the GABRG2 gene. It functions also as histamine receptor and mediates cellular responses to histamine. It functions as receptor for diazepines and various anesthetics and as ligand-gated chloride channel.
The molecules developed by companies in Pre-Registration, Phase III and Preclinical stages are 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Metabolic Disorders which include indications Sedation, General Anesthetic Effect, Hypercholesterolemia, Status Epilepticus and Substance (Drug) Abuse.
Furthermore, this report also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)
- The report reviews Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
The nucleotides market is expected to grow at a CAGR of over 8% during the forecast period. The major factor driving the market studied is the growing demand for nucleotides from pharmaceuticals and Increased Demand due to the COVID-19 Outbreak. On the flip side, the high manufacturing cost of nucleotides are hindering the growth of the market. -...
Pharmaceutical Membrane Filtration Market Report Overview Pharmaceutical Membrane Filtration market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Pharmaceutical Membrane Filtration market types and applications. It is a focused study on...
400 pages •
By The Business Research Company
• Feb 2021
Major companies in the pharmaceutical drug market include Novartis AG; Sanofi S.A.; Pfizer Inc.; Gilead Sciences, Inc. and Johnson & Johnson. The global pharmaceutical drugs market is expected to grow from $975.04 billion in 2020 to $981.73 billion in 2021 at a compound annual growth rate (CAGR) of 0.7%. The growth is mainly due to...
The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period. The protein A resin market has witnessed increasing consumption due to increased monoclonal antibody production on account of the pandemic situation worldwide.. Growth in the market can primarily...
120 pages •
By Infiniti Research Limited
• Jan 2021
Global Lactase Enzyme Market 2021-2025
The analyst has been monitoring the lactase enzyme market and it is poised to grow by $ 131.55 mn during 2021-2025 progressing at a CAGR of 4% during the forecast period. Our report on lactase enzyme market provides a holistic analysis, market size and forecast, trends, growth drivers,...
Iceland Pharmaceutical Market Report Overview Iceland Pharmaceutical market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Iceland Pharmaceutical market types and applications. It is a focused study on Iceland Pharmaceutical market space...
United States Active Pharmaceutical Ingredient Market, By Method of Synthesis (Biological v/s. Synthetic), By Source (In-house v/s Contract Manufacturing Organizations), By Distribution Channel (Online v/s Offline), By Therapeutic Application (Cardiovascular Disease, Anti-diabetic, Oncology, Neurological Disorders, Musculoskeletal,...
Global Biochip Market By Type (DNA Chips, Lab-On-a-Chips & Protein Chips), By Technology (Microarray v/s Microfluidics), By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Agriculture, Others), By End User (Biotechnology & Pharmaceutical Companies, Hospitals & Diagnostics Centers, Academic & Research...
The lactic acid market is estimated to be valued at USD 1.1 billion in 2020 and is projected to reach USD 2.1 billion by 2025, recording a CAGR of 12.8%, in terms of value. The polylactic acid market is estimated to be valued at USD 786 million in 2020 and is projected to reach USD 1,756 million by 2025, recording a CAGR of 17.4%, in terms...
Beverage
Pharmaceutical
Infectious Disease
World
APAC
Europe
North America
Greenhouse Gas Emissions
Gross Domestic Product
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.